A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
ENGLEWOOD, CO / December 5, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that MiOXSYS® will be featured in a Product Symposium at the 8th...
ENGLEWOOD, CO / December 3, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Josh Disbrow, Chairman and Chief Executive...
Acerus Launches U.S. Specialty Sales Force; Sales Team Expansion Nearly Doubles Current Natesto Sales Force Expanded Commercial Operations Expected to Accelerate Natesto Growth in the U.S. ENGLEWOOD, CO / December 2, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a...
Provides More Than Six Million US Lives Unrestricted Access to Only FDA-Approved 12-Hour Codeine-Based Cold-Cough Syrup ENGLEWOOD, CO / November 19, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of...
ENGLEWOOD, CO / November 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today will provide an overview of its business, including the...
ENGLEWOOD, CO / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the hiring of Matthew Phillips as the company's...
ENGLEWOOD, CO / November 7, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results...
Asset Purchase Increases Combined Company Annual Revenue to $44M, Including Previously Announced Acquisition of Innovus Pharmaceuticals Over $5 Million in Near-Term Cost Savings Expected Through Efficient Sales Force Integration and Removal of Redundant Operations...
Tuzistra XR Now Covered on Commercial Plans Covering Over 30 Million U.S. Lives U.S. Cough Cold Prescription Market is Worth in Excess of $3 Billion at Current Brand Pricing, with 30-35 Million Prescriptions Written Annually ENGLEWOOD, CO / October 21, 2019 / Aytu...
Phase IV, Investigator-Initiated Study is First to Conclusively Show that a Testosterone Replacement Therapy (TRT) Maintains Key Fertility Measures in Men with Low T Natesto Increased Serum Testosterone and Improved Hypogonadal Symptoms While Simultaneously...